在癌症中对RAS抑制的反应和抵抗
Richard Y Ebright1,2,3, Julien Dilly1,2,3, Alice T Shaw1,2
1Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.
Cancer discovery
|April 28, 2025
概括
拉斯抑制剂在治疗各种癌症方面表现有前途,但耐药性限制了它们的有效性. 未来的策略需要开发优质抑制剂和组合疗法,以克服耐药性并改善患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 在许多人类癌症中,RAS通路突变很普遍.
- 拉斯抑制剂已经在各种癌症类型中表现出初始疗效.
- 获得的耐药性机制显著阻碍了针对RAS的治疗方法的长期临床益处.
研究的目的:
- 审查RAS抑制剂在癌症治疗中的当前情况.
- 识别克服获得抵抗的关键挑战和机会.
- 概述开发下一代RAS向治疗和组合的策略.
主要方法:
- 对RAS抑制剂的临床前和临床研究的文献综述.
- 分析与RAS向治疗相关的耐药机制.
- 评估新兴药物开发和组合治疗方法.
主要成果:
- 早期临床试验证实了RAS抑制剂在各种恶性瘤中的活性.
- 获得的耐药性是治疗失败的主要原因之一.
- 开发具有强度,选择性和药理动学的抑制剂至关重要.
结论:
- 克服获得的耐药性对于最大限度地提高RAS向治疗的临床影响至关重要.
- 下一代抑制剂和合理的组合策略对于持久的反应是必要的.
- 对抗性机制的进一步研究将指导开发更有效的癌症治疗方法.
更多相关视频
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
10.5K
12:22The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
33.5K
相关概念视频
The Ras Gene
6.1K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.1K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
mTOR Signaling and Cancer Progression
3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.6K
Small GTPases - Ras and Rho
3.8K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
3.8K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Interactions Between Signaling Pathways
6.1K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.1K
